Exploring the Insights on Exosomes and their Utility in Treating Ophthalmic Disease: Delving into the Clinical Approval and Present Trials

IF 2.8 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current drug delivery Pub Date : 2024-09-18 DOI:10.2174/0115672018324046240905134931

Ashish Ranjan Dwivedi, Yogesh Murti, Pramod Rawat, Shriya Mahajan, Harsimrat Kandhari, Gaurav Joshi, Bhupinder Kumar

{"title":"Exploring the Insights on Exosomes and their Utility in Treating Ophthalmic Disease: Delving into the Clinical Approval and Present Trials","authors":"Ashish Ranjan Dwivedi, Yogesh Murti, Pramod Rawat, Shriya Mahajan, Harsimrat Kandhari, Gaurav Joshi, Bhupinder Kumar","doi":"10.2174/0115672018324046240905134931","DOIUrl":null,"url":null,"abstract":": Ophthalmic diseases include a wide array of conditions, each requiring individualized treatment approaches. In ophthalmic research and as therapeutics against potential pharmacological indications, several subtypes of exosomes (EVs) have been reconnoitered, mainly for their regenerative, neuroprotective, and anti-inflammatory characteristics. EVs are recently gaining wider attention as promising vehicles for therapies because of their natural participation in communication between cells and targeted delivery. These small vesicles, derived from cells, transport numerous molecules between cells, thus contributing advantages like low immunogenicity, stability, and the ability to target cells specifically. These inherent advantages of carrying the therapeutic cargo and enabling intercellular signaling make them a captivating avenue for progressing ophthalmic disease treatment options. While research is ongoing, and clinical applications are still emerging, several EV subtypes have shown promise for possible applications in addressing several ophthalmic diseases, such as glaucoma, age-related macular degenerative disorders, retinal degenerative disorders, and ocular inflammatory conditions.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":"211 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115672018324046240905134931","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

: Ophthalmic diseases include a wide array of conditions, each requiring individualized treatment approaches. In ophthalmic research and as therapeutics against potential pharmacological indications, several subtypes of exosomes (EVs) have been reconnoitered, mainly for their regenerative, neuroprotective, and anti-inflammatory characteristics. EVs are recently gaining wider attention as promising vehicles for therapies because of their natural participation in communication between cells and targeted delivery. These small vesicles, derived from cells, transport numerous molecules between cells, thus contributing advantages like low immunogenicity, stability, and the ability to target cells specifically. These inherent advantages of carrying the therapeutic cargo and enabling intercellular signaling make them a captivating avenue for progressing ophthalmic disease treatment options. While research is ongoing, and clinical applications are still emerging, several EV subtypes have shown promise for possible applications in addressing several ophthalmic diseases, such as glaucoma, age-related macular degenerative disorders, retinal degenerative disorders, and ocular inflammatory conditions.

查看原文本刊更多论文

探索外泌体及其在治疗眼科疾病中的作用：深入了解临床批准和当前试验

:眼科疾病种类繁多，每种疾病都需要个性化的治疗方法。在眼科研究和针对潜在药理适应症的治疗中，已经发现了几种亚型的外泌体（EVs），主要用于再生、神经保护和抗炎。由于外泌体可自然参与细胞间的交流和靶向递送，因此作为有前景的治疗载体，外泌体最近正受到越来越广泛的关注。这些源自细胞的小囊泡可在细胞间运输多种分子，因此具有免疫原性低、稳定性强、可特异性靶向细胞等优点。这些固有的携带治疗货物和实现细胞间信号传递的优势，使它们成为眼科疾病治疗方案取得进展的迷人途径。虽然研究仍在进行，临床应用也在不断涌现，但有几种 EV 亚型已显示出有望应用于治疗几种眼科疾病，如青光眼、老年性黄斑变性疾病、视网膜变性疾病和眼部炎症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug delivery PHARMACOLOGY & PHARMACY-

CiteScore

5.10

自引率

4.20%

发文量

170

期刊介绍： Current Drug Delivery aims to publish peer-reviewed articles, research articles, short and in-depth reviews, and drug clinical trials studies in the rapidly developing field of drug delivery. Modern drug research aims to build delivery properties of a drug at the design phase, however in many cases this idea cannot be met and the development of delivery systems becomes as important as the development of the drugs themselves. The journal aims to cover the latest outstanding developments in drug and vaccine delivery employing physical, physico-chemical and chemical methods. The drugs include a wide range of bioactive compounds from simple pharmaceuticals to peptides, proteins, nucleotides, nucleosides and sugars. The journal will also report progress in the fields of transport routes and mechanisms including efflux proteins and multi-drug resistance. The journal is essential for all pharmaceutical scientists involved in drug design, development and delivery.